| Not Yet Recruiting | R21/MM Dosing, Presentations, and Preservatives NCT07194668 | University of Oxford | Phase 4 |
| Active Not Recruiting | Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vacci NCT06549257 | University of Oxford | Phase 1 / Phase 2 |
| Recruiting | Mass Vaccine and Drug Administration, Bangladesh NCT06068530 | University of Oxford | Phase 4 |
| Completed | Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites. NCT04577066 | Leiden University Medical Center | Phase 1 / Phase 2 |
| Terminated | Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Inf NCT04300309 | Novartis Pharmaceuticals | Phase 2 / Phase 3 |
| Unknown | Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand NCT05052502 | University of California, San Francisco | N/A |
| Unknown | Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Repub NCT04416945 | University of California, San Francisco | N/A |
| Completed | Additional Screening With Sensitives RDTs and Malaria NCT04147546 | Institut de Recherche en Sciences de la Sante, Burkina Faso | Phase 3 |
| Completed | Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine NCT05192265 | University of Ibadan | Phase 2 / Phase 3 |
| Completed | Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia NCT03996967 | Boston University | — |
| Completed | Mass Screening and Treatment for Reduction of Falciparum Malaria NCT04093765 | University of Oxford | N/A |
| Unknown | Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) fo NCT03462615 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Completed | Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic NCT03783299 | University of California, San Francisco | Phase 4 |
| Completed | Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in NCT03773536 | Professor Anders Björkman | Phase 4 |
| Completed | SJ733 Induced Blood Stage Malaria Challenge Study NCT02867059 | Medicines for Malaria Venture | Phase 1 |
| Completed | DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax NCT02123290 | Medicines for Malaria Venture | Phase 2 |
| Completed | Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Ma NCT02614404 | HuLow | Phase 1 |
| Completed | DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria NCT02450578 | Medicines for Malaria Venture | Phase 1 |
| Terminated | Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosqu NCT02543086 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S NCT02252640 | University of Oxford | Phase 1 / Phase 2 |
| Completed | Malaria in Early Life Study NCT02001428 | Gadjah Mada University | N/A |
| Completed | Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Admini NCT02237586 | Sanaria Inc. | Phase 1 |
| Completed | Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoite NCT02115516 | Sanaria Inc. | Phase 1 |
| Completed | Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenou NCT02132299 | Sanaria Inc. | Phase 1 |
| Completed | A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine NCT02044198 | University of Oxford | Phase 1 / Phase 2 |
| Completed | A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S NCT01883609 | University of Oxford | Phase 1 / Phase 2 |
| Completed | Targeted Chemo-elimination (TCE) of Malaria NCT01872702 | University of Oxford | N/A |
| Completed | A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Appro NCT01739036 | University of Oxford | Phase 1 / Phase 2 |
| Completed | Artemisinin-resistant Malaria in Cambodia NCT01736319 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria. NCT02089841 | Richard Mwaiswelo | Phase 4 |
| Completed | A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine Candidates NCT01623557 | University of Oxford | Phase 1 / Phase 2 |
| Completed | Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis NCT01218893 | Radboud University Medical Center | N/A |
| Completed | Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroqui NCT01236612 | Radboud University Medical Center | N/A |
| Completed | Superiority of ArTiMist Versus Quinine in Children With Severe Malaria NCT01258049 | Proto Pharma Ltd | Phase 3 |
| Completed | EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria NCT01169077 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults NCT01026246 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Withdrawn | Phase 1 Study of the Safety and Immunogenicity of a Malaria Transmission-blocking Pfs25-Pfs25 Conjugate Vaccin NCT00977899 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1 |
| Completed | Rapid Diagnostic Tests for Assessment of Initial Clearance and Detection of Recurrent Malaria Infections NCT01843764 | Anders Björkman | — |
| Completed | Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar NCT02792816 | Department of Medical Research, Lower Myanmar | — |
| Completed | Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy NCT00701961 | Institute of Tropical Medicine, Belgium | Phase 2 / Phase 3 |
| Completed | Malarial Immunity in Pregnant Cameroonian Women NCT00593398 | University of Hawaii | — |
| Completed | Hyperphenylalaninemia in Cerebral Malaria NCT00338520 | University of Utah | — |
| Completed | The Cytoadherence in Pediatric Malaria (CPM) Study NCT00707200 | University Health Network, Toronto | — |
| Completed | Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand NCT01659281 | Armed Forces Research Institute of Medical Sciences, Thailand | N/A |
| Completed | Plasmodium Resistance in A. Gambiae NCT00466557 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali NCT00460525 | U.S. Army Medical Research and Development Command | Phase 2 |
| Completed | Phase I Pediatric FMP2.1/AS02A Trial in Mali NCT00358332 | U.S. Army Medical Research and Development Command | Phase 1 |
| Completed | Malaria Transmission and Immunity in Highland Kenya NCT00393757 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Fetal Immunity to Falciparum Malaria NCT00314899 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Malaria Prevalence in Children NCT00322816 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Time to Infection With Malaria Parasites NCT00322738 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | RBx11160 Phase II Dose Ranging Study RBx/MMV05-06 NCT00362050 | Medicines for Malaria Venture | Phase 2 |
| Completed | Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly NCT00347555 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria NCT00484900 | Dafra Pharma | Phase 3 |
| Completed | Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America NCT00312702 | U.S. Army Medical Research and Development Command | Phase 1 / Phase 2 |
| Completed | Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America NCT00312663 | U.S. Army Medical Research and Development Command | Phase 1 / Phase 2 |
| Completed | Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers NCT00730782 | European Vaccine Initiative | Phase 1 |
| Completed | Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria NCT01594931 | Medicines for Malaria Venture | Phase 2 |
| Completed | AMA1-C1/Alhydrogel + CpG 7909 for Malaria NCT00344539 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi NCT00125489 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 |
| Completed | Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005 NCT03768908 | Professor Anders Björkman | Phase 4 |
| Completed | FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali NCT00349713 | U.S. Army Medical Research and Development Command | Phase 1 |
| Completed | Human Immunity to MSP-1 in Western Kenya NCT00138372 | Case Western Reserve University | — |
| Completed | Experimental Vaccine for Plasmodium Falciparum Malaria NCT00340431 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Experimental Vaccine for Malaria in Adults in Mali NCT00343005 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Trial to Assess the Efficacy of Malaria Vaccine PfCS 102 NCT01031524 | Swiss Tropical & Public Health Institute | Phase 1 / Phase 2 |
| Completed | Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of NCT00074841 | Pfizer | Phase 2 / Phase 3 |
| Completed | Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children NCT00317473 | U.S. Army Medical Research and Development Command | Phase 1 |
| Terminated | Comparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status NCT00304980 | Institute of Tropical Medicine, Belgium | N/A |
| Completed | Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar NCT03764527 | Professor Anders Björkman | Phase 4 |
| Completed | Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Unco NCT00709969 | Novartis | Phase 3 |
| Completed | ICC-1132 - Candidate Vaccine Against P Falciparum Malaria NCT00587249 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Terminated | Pentoxifylline in Children With Malaria NCT00133393 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Withdrawn | CS DNA MVA Trial in Mampong, Ghana NCT00377494 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Azithromycin Combination Therapy for Malaria NCT00299208 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Withdrawn | SP Resistance and Falciparum Malaria Transmission NCT00299247 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |